Cortisol and Glucocorticoids part 3 of 3: Prednisone, Dexamethasone & Clinical Tradeoffs

In this third lecture on cortisol and glucocorticoids, we transition from receptor biology into clinical pharmacology and medicinal chemistry. We explore how small structural changes to cortisol give rise to widely used therapeutic drugs like prednisone and dexamethasone — and how those changes dramatically alter potency, receptor selectivity, duration of action, and side effect profiles. Topics covered in this lecture: • Prednisone as a prodrug and hepatic activation • Dexamethasone as a potent, long-acting, GR-selective glucocorticoid • Why tapering steroid therapy is critical (HPA axis suppression) • Metabolic and cardiovascular risks of long-term glucocorticoid use • Glucocorticoids in the brain — context-dependent effects • Clinical tradeoffs: adjustable vs. potent, enzyme-dependent vs. direct-acting • Therapeutic effects vs. side effects — why they arise from the same receptor biology • Dexamethasone in COVID-19 inflammatory management This lecture emphasizes the core medicinal chemistry principle that small structural changes can produce large functional consequences — and shows how structure–activity relationships (SAR) directly shape clinical outcomes. Ideal for students in: • Medicinal Chemistry • Pharmacology • Endocrinology • Pre-Medical and Health Sciences • Pharmacy Parts 1 & 2 cover hormone signaling, the HPA axis, glucocorticoid receptors, and cortisol structure.